To address this evidence gap, we performed a Bayesian network meta-analysis to compare the efficacy and safety of SGLT2 inhibitors, GLP-1 receptor agonists, and sulfonylureas in patients with T2DM and HF. The gene discussed is GLP1R; the disease is hydrops fetalis.